Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed glioblastoma multiforme~  * Supratentorial~ * Grade IV astrocytoma~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9.0 g/dL~Hepatic~* Bilirubin no greater than 1.5 mg/dL~* Transaminases no greater than 4 times upper limit of normal~Renal~* Creatinine no greater than 1.7 mg/dL~* Creatinine clearance at least 60 mL/min~* No prior renal toxicity with nonsteroidal anti-inflammatory drugs~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Mini mental score at least 15~* No history of peptic disease~* No serious concurrent infection~* No other medical illness that would preclude study participation~* No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer~* No allergy to sulfonamides~* Able to tolerate cyclo-oxygenase-2 (COX-2) inhibitors~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy or biologic agents for the malignancy, including any of the following:~  * Immunotoxins~ * Immunoconjugates~ * Antisense agents~ * Peptide receptor antagonists~ * Interferons~ * Interleukins~ * Tumor-infiltrating lymphocytes~ * Lymphokine-activated killer cells~ * Gene therapy~* No concurrent prophylactic growth factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])~Chemotherapy~* No prior chemotherapy for the malignancy~Endocrine therapy~* No prior hormonal therapy for the malignancy~* Prior glucocorticoid therapy allowed~* Concurrent corticosteroids allowed provided there has been no dose increase within the past 5 days~Radiotherapy~* No prior radiotherapy for the malignancy~Surgery~* Recovered from prior surgery~Other~* At least 1 week since prior fluconazole~* More than 10 days since prior anticonvulsant drugs that induce hepatic metabolic enzymes (Group A)~* No other prior therapy for the malignancy~* No concurrent enrollment in another therapeutic clinical trial~* No concurrent fluconazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- p450 ( +EIASD) (Type: ACTIVE_COMPARATOR): on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm
- nonp450 (-EIASD) (Type: ACTIVE_COMPARATOR): not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility